FDAnews
www.fdanews.com/articles/81499-repligen-begins-clinical-study-of-secretin-in-schizophrenia

REPLIGEN BEGINS CLINICAL STUDY OF SECRETIN IN SCHIZOPHRENIA

October 7, 2005

Repligen has launched a follow-on study to assess the impact of RG1068, synthetic human secretin, on a surrogate marker for a cognitive deficit characteristic of patients with schizophrenia. This study is being conducted to determine if the preliminary finding that secretin may have had an impact on a cognitive deficit in schizophrenia is reproducible and related to drug treatment.

Thirty patients will be assigned to one of two double-blind treatment groups, subcutaneous saline or subcutaneous RG1068. Additional assessments will be made on the patients to investigate the effects of RG1068 on information-processing and affect modulation.